Has Naila Goldenberg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $47,621 in general payments to Naila Goldenberg, MD across 1,441 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Naila Goldenberg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Naila Goldenberg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Naila Goldenberg, MD

Endocrinology, Diabetes & Metabolism · Mason, OHNPI 1396796330

Payments from drug & device makers

$47,621in general payments, 2019–2025

Across 1,441 payments — averaging $33.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk AS$11K
Sanofi-aventis U.S. LLC$10K
Regeneron Healthcare Solutions, Inc.$4K
Novo Nordisk$2K
Corcept Therapeutics$2K
Lilly USA, LLC$2K
plus $16K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk AS	6	$11,050
Sanofi-aventis U.S. LLC	56	$9,551
Regeneron Healthcare Solutions, Inc.	40	$3,836
Novo Nordisk	166	$2,487
Corcept Therapeutics	52	$2,124
Lilly USA, LLC	145	$2,075
Amgen(2 entities)	118	$2,006
AbbVie	113	$1,547
Amarin Pharma, Inc.	98	$1,463
Mannkind Corporation	62	$981
AstraZeneca(2 entities)	29	$836
Xeris Pharmaceuticals, Inc.	55	$740
Medtronic(2 entities)	24	$691
Dexcom, Inc.	27	$647
Insulet Corporation	30	$596
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	52	$583
Boehringer Ingelheim	29	$568
Bayer	29	$425
BETA Bionics, Inc.	17	$411
Ascendis Pharma Endocrinology Inc	12	$394
Johnson & Johnson	21	$332
Nestle Healthcare Nutrition Inc.	36	$311
Antares Pharma, Inc.	13	$297
Novartis	23	$286
IBSA Pharma Inc.	12	$284
Kyowa Kirin, Inc.	10	$281
Tandem Diabetes Care, Inc.	15	$268
Kowa Pharmaceuticals America, Inc.	13	$193
Aimmune Therapeutics, Inc.	17	$191
Recordati_rare_diseases_inc.	11	$185
Neurocrine Biosciences, Inc.	4	$165
Clarus Therapeutics Inc.	15	$156
Pfizer	9	$153
Esperion Therapeutics, Inc.	7	$117
Regeneron	1	$114
Lifescan, Inc.	7	$107
Radius Health, Inc.	6	$107
Amneal Pharmaceuticals LLC	6	$105
Sequel Med Tech, LLC	3	$89
Ultragenyx Pharmaceutical Inc.	4	$87
Shire North American Group Inc	5	$76
Acella Pharmaceuticals, LLC	4	$71
Merck	4	$68
Endo Pharmaceuticals Inc.	4	$56
Vivus LLC	3	$52
Phathom Pharmaceuticals, Inc.	3	$51
Abbott	3	$50
Ascensia Diabetes Care US Inc.	3	$49
Shield Therapeutics Inc	2	$40
Amphastar Pharmaceuticals, Inc.	2	$34
Tolmar, Inc.	2	$28
Eton Pharmaceuticals, Inc.	1	$23
Alvogen Inc	1	$23
Phadia US Inc.	1	$21
Eisai Inc.	1	$19
Currax Pharmaceuticals LLC	2	$19
Amryt Pharma Holdings Ltd	1	$18
Cequr Corporation	1	$18
Verity Pharmaceuticals Inc.	1	$15
Zealand Pharma US, Inc.	1	$13

How this compares

$47,621 in reported general payments places this provider in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio →

Medicare billing

Part B allowed, 2024

$29,129

Medicare patients

Services billed

307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Mason

Toby BriskinBedford$9.8M
Charles SmithCanton$5.3M
Kevin PantaloneCleveland$4M
Elena ChristofidesColumbus$3.5M
Arvind KrishnaCanton$3.1M
Bartolome BurgueraCleveland$3.1M
Steven IngColumbus$1.9M
Kathleen DunganColumbus$1.4M
Kyaw SoeColumbus$1.3M
John PaesWesterville$671K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →